This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Adverse Events (AEs)
Timeframe: Up to 90 days from last dose or study discontinuation
Number of Participants With AEs Leading to Treatment Discontinuation
Timeframe: Up to 90 days from last dose or study discontinuation
Number of Participants With Serious Adverse Events (SAEs)
Timeframe: Up to 90 days from last dose or study discontinuation
Number of Participants With AEs Leading to Death
Timeframe: Up to 90 days from last dose or study discontinuation
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com